EUVIMEDEUVIMED entdecken
Crossref

Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)

Laura F Mataseje, Nicole Lerminiaux iD, Philippe Lagacé-Wiens iD, Andrew Walkty, Heather J Adam iD, Susan Poutanen, Melanie Baxter, James A Karlowsky, Melissa McCracken, George R Golding, George G Zhanel

Journal of Antimicrobial Chemotherapy · 28.08.2025 · 80 (Supplement_2) · ii54-ii61

DOI: 10.1093/jac/dkaf221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 28.08.2025. Verfasst von Laura F Mataseje und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4, Canada. Hauptthemen laut MEDLINE: Ertapenem, Anti-Bacterial Agents, Enterobacteriaceae Infections, Enterobacteriaceae. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: University of Manitoba, Shared Health, National Microbiology Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To review phenotypic and genotypic characteristics of ertapenem-resistant Enterobacterales isolates identified by the CANWARD study from 2007 to 2023.

Methods

Bacterial isolates were collected as part of the CANWARD surveillance study from 2007 to 2023. CLSI M7 broth microdilution antimicrobial susceptibility testing (12th edition, 2024) was performed. MICs were interpreted by CLSI M100 breakpoints (34th edition, 2024). WGS was performed to identify antimicrobial resistance markers.

Results

Only 134 (0.7%) of the 19 642 Enterobacterales were ertapenem-resistant. Carbapenemase producing Enterobacterales (CPE) accounted for 17.9% (n = 24) of ertapenem-resistant isolates and were predominantly Klebsiella pneumoniae (54.2%) and Escherichia coli (20.8%). KPC was the most common carbapenemase identified (62.5%). K. pneumoniae ST834, ST16 and ST258, and E. coli ST131 were the most frequent STs detected. CPE percent resistant values ranged from 20.8% to 25.0% for ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam. Most non-CPE ertapenem-resistant isolates were Enterobacter spp. (51.8%), E. coli (15.5%) and K. pneumoniae (10.9%). Non-CPE STs were most commonly E. cloacae ST108, ST50 and ST133, and E. coli ST131. Non-CPE percent resistant values ranged from 2.7% to 4.5% for ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam. At least one of an AmpC, an ESBL or porin alternations were observed in most non-CPE isolates.

Conclusions

In Canada, ertapenem-resistant Enterobacterales remain uncommon (0.7%). CPE isolates demonstrated higher percent resistant values for multiple antimicrobial classes and harboured more antimicrobial resistance genes than non-CPE isolates. Continued monitoring for ertapenem-resistant Enterobacterales, particularly CPE, is important given their associated multidrug resistance to both established and newer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErtapenemAnti-Bacterial AgentsEnterobacteriaceae InfectionsEnterobacteriaceaeHumansMicrobial Sensitivity TestsCanadaHospitalsbeta-LactamasesBacterial ProteinsKlebsiella pneumoniaeEscherichia coliWhole Genome SequencingDrug Resistance, Multiple, Bacterial

Substanzen

ErtapenemAnti-Bacterial Agentsbeta-LactamasesBacterial Proteinscarbapenemase

Autor:innen und Institutionen

  • National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4, Canada.
  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9, Canada.
  • Clinical Microbiology, Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada.
  • Department of Microbiology, University Health Network/Sinai Health, 1470-600 University Avenue, Toronto, Ontario M5G 1X5, Canada.

ORCID-Profile: Nicole Lerminiaux, Philippe Lagacé-Wiens, Heather J Adam

Förderung

  • University of Manitoba
  • Shared Health
  • National Microbiology Laboratory
  • Avir Pharma Inc.
  • Iterum Therapeutics
  • Merck Canada Inc.
  • Paladin Labs
  • Pfizer

Zitieren

APA

Mataseje, L. F., Lerminiaux, N., Lagacé-Wiens, P., Walkty, A., Adam, H. J., Poutanen, S., Baxter, M., Karlowsky, J. A., McCracken, M., Golding, G. R., & Zhanel, G. G. (2025). Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy, 80(Supplement_2), ii54-ii61. https://doi.org/10.1093/jac/dkaf221

Vancouver

Mataseje LF, Lerminiaux N, Lagacé-Wiens P, Walkty A, Adam HJ, Poutanen S, et al. Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 2025;80(Supplement_2):ii54-ii61. doi:10.1093/jac/dkaf221

BibTeX
@article{Mataseje2025,
  author = {Mataseje, Laura F and Lerminiaux, Nicole and Lagacé-Wiens, Philippe and Walkty, Andrew and Adam, Heather J and Poutanen, Susan and Baxter, Melanie and Karlowsky, James A and McCracken, Melissa and Golding, George R and Zhanel, George G},
  title = {Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {Supplement_2},
  pages = {ii54--ii61},
  doi = {10.1093/jac/dkaf221}
}
Kostenlos starten →